S-23 (drug)

S-23 (drug)
	240px
Systematic (IUPAC) name
	(2S)-N-(4-cyano-3-trifluoromethylphenyl)-3-(3-fluoro-4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide
Legal status
Legal status	Investigational new drug;
Identifiers
PubChem	CID 24892822
Chemical data
Formula	C18H13ClF4N2O3
Molar mass	416.753 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTx Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment.^[1]^[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

40px	This drug article relating to the genito-urinary system is a stub. You can help ssf by expanding it. v d e

↑ Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, Bohl C, Dalton JT, Miller DD. Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. Journal of Medicinal Chemistry. 2004 Feb 12;47(4):993-8. PMID 14761201
↑ Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology. 2009 Jan;150(1):385-95. PMID 18772237